دورية أكاديمية
Treating systemic effects of COPD
| العنوان: | Treating systemic effects of COPD |
|---|---|
| المؤلفون: | CAZZOLA, MARIO, ROGLIANI, PAOLA, Matera, MG, Page, C. |
| المساهمون: | Cazzola, M, Matera, M, Rogliani, P, Page, C |
| بيانات النشر: | Elsevier Science Limited |
| سنة النشر: | 2007 |
| المجموعة: | Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca |
| مصطلحات موضوعية: | 4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole, 4 [4 (4 fluorophenyl) 1 (3 phenylpropyl) 5 (4 pyridinyl) 1h imidazol 2 yl] 3 butyn 1 ol, 4 [4 (4 fluorophenyl) 5 (2 methoxy 4 pyrimidinyl) 1 imidazolyl]cyclohexanol, acetylcysteine, angiotensin 2 receptor antagonist, antioxidant, beta 2 adrenergic receptor stimulating agent, bronchodilating agent, corticosteroid, dipeptidyl carboxypeptidase inhibitor, doramapimod, enoxaparin, etanercept, glutathione derivative, glycosaminoglycan, heparin, hydroxymethylglutaryl coenzyme A reductase inhibitor, infliximab, irbesartan, mevinolin, muscarinic receptor blocking agent, phosphodiesterase IV inhibitor, pioglitazone, rosiglitazone, selenium derivative, simvastatin, superoxide dismutase, theophylline, antiinflammatory activity, atherosclerosi |
| الوصف: | The emerging recognition that chronic obstructive pulmonary disease (COPD) is a complex disorder, characterized not only by local pulmonary inflammation, but also by systemic inflammation that might have an adverse impact on various extrapulmonary organs, such as the blood vessels and the heart, among others, emphasizes the need for new and more effective forms of therapy for this debilitating disorder. Fortunately, many of the 'standard' therapeutic options used to treat COPD have the potential to influence systemic inflammation. Moreover, several new therapeutic strategies aimed at controlling the underlying inflammatory processes of COPD more specifically are under development. Unfortunately, we still do not know whether treatment of lung inflammation decreases, for example, the risk of acute cardiac events, progression of atherosclerosis or thrombotic events. It is also unclear whether, alternatively, treatment of heart disease can affect the progression of lung disease. Nonetheless, initial data seem to indicate that drugs, such as statins, ACE inhibitors, AT1 receptor blockers and PPAR agonists, used to treat a co-morbid condition have the potential to benefit COPD patients. © 2007 Elsevier Ltd. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/17897727; info:eu-repo/semantics/altIdentifier/wos/WOS:000250635700007; volume:28; issue:10; firstpage:544; lastpage:550; journal:TRENDS IN PHARMACOLOGICAL SCIENCES; http://hdl.handle.net/2108/42211Test; info:eu-repo/semantics/altIdentifier/scopus/http://www.scopus.com/inward/record.url?eid=2-s2.0-34748904145&partnerID=40&md5=2bcff4100544d1a8d63dcb959c29eed4Test |
| DOI: | 10.1016/j.tips.2007.09.006 |
| الإتاحة: | https://doi.org/10.1016/j.tips.2007.09.006Test http://hdl.handle.net/2108/42211Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.BBE51078 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.tips.2007.09.006 |
|---|